achilles therapeutics logo

Achilles Therapeutics Ltd.

Achilles Therapeutics is focused on the development of the next generation of personalised vaccines and adoptive T cell therapies to treat metastatic cancer and is located at Stevenage Bioscience Catalyst (SBC), the open innovation campus driving collaboration to improve healthcare.

Achilles Therapeutics brings together world-class research from UCL (University College London) and the Francis Crick Institute, funded by Cancer Research UK and the National Institute for Health Research (NIHR).

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://achillestx.com
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Stevenage Bioscience Catalyst,Gunnels Wood Road, Stevenage, SG1 2FX
Hertfordshire
United Kingdom
Email
Contact Number
+44 1438 906 906

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/achillestx.com” connections=”true” suffix=””]

Achilles Therapeutics has an exclusive rights to develop and commercialise neo-antigen technologies arising from Cancer Research UKs £14m TRACERx study, which involves 850 people with non-small cell lung cancer.

In Sep 2016, Achilles Therapeutics was formed with a successful financing round of £13.2 million ($17.5 million) led by Syncona with the CRT Pioneer Fund and the UCL Technology Fund.